{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:18:49Z","timestamp":1790162329301,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.tranon.2020.100757","type":"journal-article","created":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T06:10:02Z","timestamp":1585116602000},"page":"100757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Preclinical Evaluation of Radiation-Induced Toxicity in Targeted Alpha Therapy Using [211At] NaAt in Mice: A Revisit"],"prefix":"10.1016","volume":"13","author":[{"given":"Yuwei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Watabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Kaneda-Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Ooe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Shirakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Toyoshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eku","family":"Shimosegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hatazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2020.100757_bb0005","first-page":"1132","article-title":"Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients","volume":"33","author":"Maxon","year":"1992","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tranon.2020.100757_bb0010","first-page":"664","article-title":"131I therapy in differentiated thyroid carcinoma: M","volume":"47","author":"Maheshwari","year":"1981","journal-title":"D. Anderson Hospital experience. Cancer."},{"key":"10.1016\/j.tranon.2020.100757_bb0015","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0167-8140(88)90057-6","article-title":"Relative concentration of astatine-211 and iodine-125 by human fetal thyroid and carcinoma of the thyroid in nude mice","volume":"13","author":"Cobb","year":"1988","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.tranon.2020.100757_bb0020","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.critrevonc.2018.03.012","article-title":"Radioiodine refractory differentiated thyroid cancer","volume":"125","author":"Jin","year":"2018","journal-title":"Crit Rev Oncol Hematol."},{"key":"10.1016\/j.tranon.2020.100757_bb0025","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(13)70215-8","article-title":"Definition and management of radioactive iodine-refractory differentiated thyroid cancer","volume":"2","author":"Schlumberger","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.tranon.2020.100757_bb0030","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2174\/1381612003399275","article-title":"Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy","volume":"6","author":"Zalutsky","year":"2000","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.tranon.2020.100757_bb0035","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2174\/1874471011104040321","article-title":"Toxicity and relative biological effectiveness of alpha emitting radioimmunoconjugates","volume":"4","author":"Dahle","year":"2011","journal-title":"Curr. Radiopharm."},{"key":"10.1016\/j.tranon.2020.100757_bb0040","first-page":"409","article-title":"Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer","volume":"21","author":"Andersson","year":"2001","journal-title":"Anticancer Res."},{"key":"10.1016\/j.tranon.2020.100757_bb0045","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","article-title":"225Ac-PSMA-617 for PSMA-Targeted alpha-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tranon.2020.100757_bb0050","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/1097-0142(19940201)73:3+<1038::AID-CNCR2820731343>3.0.CO;2-8","article-title":"Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131I-Lym-1 as a model","volume":"73","author":"DeNardo","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.tranon.2020.100757_bb0055","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","article-title":"Targeted alpha-therapy of metastatic castration-resistant prostate cancer with (225)Ac-PSMA-617: dosimetry estimate and empiric dose finding","volume":"58","author":"Kratochwil","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tranon.2020.100757_bb0060","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients","volume":"58","author":"Rahbar","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tranon.2020.100757_bb0065","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2967\/jnumed.118.222638","article-title":"Enhancement of (211)At uptake via the sodium iodide symporter by the addition of ascorbic acid in targeted alpha-therapy of thyroid cancer","volume":"60","author":"Watabe","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.tranon.2020.100757_bb0070","doi-asserted-by":"crossref","unstructured":"Andersson M, Johansson L, Eckerman K, Mattsson S. IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms. EJNMMI Res. 2017;7:88.","DOI":"10.1186\/s13550-017-0339-3"},{"key":"10.1016\/j.tranon.2020.100757_bb0075","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/096032719000900505","article-title":"The effect of the alpha-particle emitter astatine-211 in the mouse at the minimum toxic dose","volume":"9","author":"Cobb","year":"1990","journal-title":"Hum Exp Toxicol."},{"key":"10.1016\/j.tranon.2020.100757_bb0080","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3181\/00379727-93-22835","article-title":"Gastric iodide and chloride clearances in dogs","volume":"93","author":"Howell","year":"1956","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.tranon.2020.100757_bb0085","first-page":"2","article-title":"The sodium-iodine symporter and the proton-pump inhibitors in - related to the side effects of- the treatment of thyroid cancer with iodine-131","volume":"10","author":"Sfakianakis","year":"2007","journal-title":"Hell J Nucl Med."},{"key":"10.1016\/j.tranon.2020.100757_bb0090","doi-asserted-by":"crossref","unstructured":"Upadhyaya A, Meng Z, Wang P, et al. Effects of first radioiodine ablation on functions of salivary glands in patients with differentiated thyroid cancer. Medicine (Baltimore). 2017;96:e7164.","DOI":"10.1097\/MD.0000000000007164"},{"key":"10.1016\/j.tranon.2020.100757_bb0095","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000468927","article-title":"Radioiodine ablation following thyroidectomy for differentiated thyroid cancer: literature review of utility, dose, and toxicity","volume":"6","author":"Andresen","year":"2017","journal-title":"Eur Thyroid J."},{"key":"10.1016\/j.tranon.2020.100757_bb0100","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1097\/MNM.0000000000000132","article-title":"Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma","volume":"35","author":"Fard-Esfahani","year":"2014","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/j.tranon.2020.100757_bb0105","first-page":"283","article-title":"The accumulation, metabolism and biological effects of astatine in rats and monkeys","volume":"2","author":"Hamilton","year":"1953","journal-title":"Univ Calif Publ Pharmacol."},{"key":"10.1016\/j.tranon.2020.100757_bb0110","unstructured":"Hamilton JG, Durbin, P.W., and Parrott, M.W. Comparison of acute and chronic changes produced in rats by iodine-131 and astatine-211 at lethal levels. Preliminary clinical data on the uptake of astatine in patients with thyroid disease. Animal physiology and pathology 2 1954:12."},{"key":"10.1016\/j.tranon.2020.100757_bb0115","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1177\/096032718800700602","article-title":"Toxicity of astatine-211 in the mouse","volume":"7","author":"Cobb","year":"1988","journal-title":"Hum. Toxicol."},{"key":"10.1016\/j.tranon.2020.100757_bb0120","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1210\/jc.2011-2532","article-title":"Update in lipid alterations in subclinical hypothyroidism","volume":"97","author":"Pearce","year":"2012","journal-title":"The Journal of Clinical Endocrinology & Metabolism."},{"key":"10.1016\/j.tranon.2020.100757_bb0125","first-page":"147","article-title":"Thyroid functions and serum lipid profile in metabolic syndrome","volume":"40","author":"Gutch","year":"2017","journal-title":"Biom. J."},{"key":"10.1016\/j.tranon.2020.100757_bb0130","first-page":"79","article-title":"Relationship between hypothyroidism and cholesterol out of the records of 1756 patients","volume":"105","author":"Sampaolo","year":"2014","journal-title":"Recenti Prog. Med."},{"key":"10.1016\/j.tranon.2020.100757_bb0135","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0021-9150(00)00537-2","article-title":"Hyperhomocysteinemia and hypercholesterolemia associated with hypothyroidism in the third US National Health and Nutrition Examination Survey","volume":"155","author":"Morris","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.tranon.2020.100757_bb0140","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/ajcp\/61.6.785","article-title":"A biochemical profile of abnormalities in hypothyroidism","volume":"61","author":"Chertow","year":"1974","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.tranon.2020.100757_bb0145","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1172\/JCI101090","article-title":"Serum lipoids and proteins in hypothyroidism","volume":"18","author":"Gildea","year":"1939","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tranon.2020.100757_bb0150","first-page":"657","article-title":"Biodistribution and dosimetry of free 211At, 125I- and 131I- in rats","volume":"28","author":"Spetz","year":"2013","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.tranon.2020.100757_bb0155","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00259-017-3919-6","article-title":"Antitumor effects of radionuclide treatment using alpha-emitting meta-(211)At-astato-benzylguanidine in a PC12 pheochromocytoma model","volume":"45","author":"Ohshima","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.tranon.2020.100757_bb0160","article-title":"Transcriptional response in mouse thyroid tissue after 211At administration: effects of absorbed dose","volume":"10","author":"Rudqvist","year":"2015","journal-title":"Initial Dose-Rate and Time after Administration. PLoS One."},{"key":"10.1016\/j.tranon.2020.100757_bb0165","doi-asserted-by":"crossref","unstructured":"Langen B, Rudqvist N, Parris TZ, et al. Transcriptional response in normal mouse tissues after i.v. (211)At administration - response related to absorbed dose, dose rate, and time. EJNMMI Res. 2015;5:1.","DOI":"10.1186\/s13550-014-0078-7"},{"key":"10.1016\/j.tranon.2020.100757_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151330","article-title":"Long-term toxicity of 213Bi-labelled BSA in mice","volume":"11","author":"Dorso","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2020.100757_bb0175","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1158\/1078-0432.CCR-07-1250","article-title":"Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2\/neu diabodies","volume":"14","author":"Robinson","year":"2008","journal-title":"Clin. Cancer Res."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523320300267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523320300267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T14:37:56Z","timestamp":1761835076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523320300267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S1936523320300267"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2020.100757","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical Evaluation of Radiation-Induced Toxicity in Targeted Alpha Therapy Using [211At] NaAt in Mice: A Revisit","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2020.100757","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100757"}}